OrthoPediatrics Corp. (NASDAQ:KIDS) Receives $24.44 Consensus PT from Brokerages

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have earned a consensus rating of “Moderate Buy” from the eleven analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $24.4444.

KIDS has been the topic of several analyst reports. TD Cowen reissued a “buy” rating on shares of OrthoPediatrics in a research report on Monday. Canaccord Genuity Group set a $25.00 price target on OrthoPediatrics in a research report on Friday, April 24th. Weiss Ratings reiterated a “sell (e+)” rating on shares of OrthoPediatrics in a research note on Tuesday, April 21st. Needham & Company LLC increased their price objective on OrthoPediatrics from $26.00 to $30.00 and gave the company a “buy” rating in a report on Friday, February 27th. Finally, BTIG Research reissued a “buy” rating and issued a $24.00 price objective on shares of OrthoPediatrics in a research note on Friday, May 1st.

Hedge Funds Weigh In On OrthoPediatrics

A number of institutional investors have recently modified their holdings of KIDS. Russell Investments Group Ltd. lifted its stake in shares of OrthoPediatrics by 433.1% in the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after buying an additional 1,139 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in OrthoPediatrics by 5,226.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after buying an additional 2,561 shares during the last quarter. Caption Management LLC bought a new position in OrthoPediatrics in the 3rd quarter worth $54,000. BNP Paribas Financial Markets raised its holdings in OrthoPediatrics by 60.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after acquiring an additional 1,235 shares during the period. Finally, State of Wyoming lifted its position in OrthoPediatrics by 189.7% during the 4th quarter. State of Wyoming now owns 6,822 shares of the company’s stock worth $121,000 after acquiring an additional 4,467 shares during the last quarter. Institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Price Performance

NASDAQ KIDS opened at $18.87 on Friday. The company has a quick ratio of 2.37, a current ratio of 5.21 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $484.58 million, a PE ratio of -11.23 and a beta of 1.03. OrthoPediatrics has a 12-month low of $14.42 and a 12-month high of $23.70. The company has a 50 day moving average price of $17.32 and a two-hundred day moving average price of $17.42.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.04. OrthoPediatrics had a negative net margin of 16.31% and a negative return on equity of 7.01%. The company had revenue of $59.36 million for the quarter, compared to analyst estimates of $58.29 million. As a group, equities analysts predict that OrthoPediatrics will post -1.13 earnings per share for the current fiscal year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.